Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
mathstodon.xyz is one of the many independent Mastodon servers you can use to participate in the fediverse.
A Mastodon instance for maths people. We have LaTeX rendering in the web interface!

Administered by:

Server stats:

2.8K
active users

mathstodon.xyz: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.8

#PASC

3 posts3 participants1 post today
Public
Tom Kindlon

Need for awareness & surveillance of long-term #postCOVID neurodegenerative disorders. A position paper from the neuroCOVID‐19 task force of the European Academy of Neurology

link.springer.com/article/10.1

"An increase in the incidence of neurodegenerative diseases might be expected”

@longcovid
#LongCovid #PwLC #PostCovidSyndrome #LC #PASC #CovidBrain @covid19 #COVIDー19 #COVID19 #COVID #COVID_19 #SARSCoV2 @novid@chirp.social #novid @novid@a.gup.pe #CovidIsNotOver #auscovid19

SpringerLinkNeed for awareness and surveillance of long-term post-COVID neurodegenerative disorders. A position paper from the neuroCOVID‐19 task force of the European Academy of Neurology - Journal of NeurologyBackground Neuropathological and clinical studies suggest that infection with SARS-CoV-2 may increase the long-term risk of neurodegeneration. Methods We provide a narrative overview of pathological and clinical observations justifying the implementation of a surveillance program to monitor changes in the incidence of neurodegenerative disorders in the years after COVID-19. Results Autopsy studies revealed diverse changes in the brain, including loss of vascular integrity, microthromboses, gliosis, demyelination, and neuronal- and glial injury and cell death, in both unvaccinated and vaccinated individuals irrespective of the severity of COVID-19. Recent data suggest that microglia play an important role in sustained COVID-19-related inflammation, which contributes to the etiology initiating a neurodegenerative cascade, to the worsening of pre-existing neurodegenerative disease or to the acceleration of neurodegenerative processes. Histopathological data have been supported by neuroimaging, and epidemiological studies also suggested a higher risk for neurodegenerative diseases after COVID-19. Conclusions Due to the high prevalence of COVID-19 during the pandemic, healthcare systems should be aware of, and be prepared for a potential increase in the incidence of neurodegenerative diseases in the upcoming years. Strategies may include follow-up of well-described cohorts, analyses of outcomes in COVID-19-registries, nationwide surveillance programs using record-linkage of ICD-10 diagnoses, and comparing the incidence of neurodegenerative disorders in the post-pandemic periods to values of the pre-pandemic years. Awareness and active surveillance are particularly needed, because diverse clinical manifestations due to earlier SARS-CoV-2 infections may no longer be quoted as post-COVID-19 symptoms, and hence, increasing incidence of neurodegenerative pathologies at the community level may remain unnoticed.
Public
Tom Kindlon

From Sweden:

Complement activation was not increased in patients with post-acute sequelae after mild SARS-CoV-2 infection: A prospective cohort study

medrxiv.org/content/10.1101/20

Screenshot is from the latest Science for ME weekly update

@longcovid
#LongCovid #PASC #PwLC #postcovid #postcovid19 #LC #Covidlonghaulers #PostCovidSyndrome #longhaulers #COVIDBrain #NeuroPASC
@covid19 #Coronavirus
#COVID19 #COVID #COVID_19 #COVIDー19 #SARSCoV2 #CovidIsNotOver
@auscovid19 #auscovid19

Preprint: MedRxiv Complement activation was not increased in patients with post-acute sequelae after mild SARS-CoV-2 infection: A prospective cohort study — Madlene Holmqvist et al. "We analyzed the complement activation markers C3bc, C3bBbP and TCC in 48 PASC patients." "Although the patients with a mild SARS-CoV-2 infection had a trend towards more severe PASC, we could not find any significant differences in complement activation markers between these patients and controls."
Public
Tom Kindlon

Long #COVID Is Associated with Severe Cognitive Limitations Among U.S. Adults

mdpi.com/2673-8112/5/4/46

"Overall, 15.1% had #longCOVID. A higher percentage of adults with long COVID (13.1% vs 4.1%) reported severe cognitive limitations compared to no COVID (p < 0.001)”

#CovidBrain #NeuroPASC @longcovid
#PwLC #PostCovidSyndrome #LC #PASC #postcovid @covid19 #COVIDー19 #COVID19 #SARSCoV2 @novid@chirp.social #novid @novid@a.gup.pe #CovidIsNotOver #auscovid19 @auscovid19

Public
Tom Kindlon

New US research funded by Dysautonomia International

Long-COVID Postural Tachycardia Syndrome: A deep phenotyping study
medrxiv.org/content/10.1101/20

"An unexpected finding of our study was that 8.7% of LC-POTS participants exhibited aggregates of P-syn on skin biopsy"

#POTS @pots #dysautonomia @dysautonomia @longcovid
#LongCovid #PwLC #PostCovidSyndrome #LC #PASC #postcovid
#CovidBrain

medRxiv · Long-COVID Postural Tachycardia Syndrome: A deep phenotyping studyBackground: Postural tachycardia syndrome (POTS) has emerged as one of the most common autonomic complications of Long-COVID (LC). However, disease mechanisms remain incompletely understood. Objectives: To evaluate the frequency and severity of autonomic dysfunction in a subset of carefully phenotyped, previously healthy patients with LC-POTS using a detailed protocol of autonomic, cerebrovascular, respiratory, blood, and tissue analyses. Methods: Participants in this study completed a battery of autonomic function tests, including measures of sudomotor, cardiovagal, and sympathetic adrenergic function, and head-up tilt (HUT) with transcranial Doppler measures of cerebral blood flow velocity (CBFv), end-tidal CO2 (ETCO2), cerebral and skeletal muscle near-infrared spectroscopy (NIRS) and plasma catecholamines. Skin biopsy was performed at proximal and distal sites and analyzed for intraepidermal nerve fiber density (IENFD) and phosphorylated α-synuclein (P-Syn). Results were compared to healthy controls (HC) ≥ 3 months post-COVID infection with no lasting sequelae. Results: LC-POTS participants (n=24) exhibited a greater increase in heart rate on HUT (31.1±20.3, p=0.01), and 38% exhibited elevated upright norepinephrine levels consistent with a hyperadrenergic response. CBFv did not significantly differ between LC-POTS and HC (n=10). EtCO2 and NIRS were also similar between groups. Twenty-two percent of LC-POTS and 38% of HC had decreased IENFD on skin biopsy, while 8.7% LC-POTS had dermal P-Syn aggregation on skin biopsy, compared to none of HC. Conclusions: LC-POTS was associated with widespread autonomic dysfunction, including orthostatic tachycardia, sympathetic adrenergic hyperactivity, small fiber neuropathy, and dermal P-Syn deposition. Our findings support the concept of multiple pathophysiological mechanisms in most patients with POTS triggered by SARS-CoV-2. ### Competing Interest Statement Dr. Larsen, Jannika Machnik, Jordan Seliger, and Ruba Shaik have nothing to disclose. Dr. Gibbons has received grant funding from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institutes of Health (NIH) and has stock options in CND Life Sciences outside the submitted work. Dr. Utz has recieved grant funding from the National Institutes of Health outside of the submitted work. Dr. Lansberg has received consulting fees from Genentech, Biogen, and Novo Nordisk and royalties from a health-related publication. Dr. Muppidi has reported receiving consulting fees from Alexion, Argenx, UCB/Ra Pharma, and Horizont Pharma and royalties from a health-related publication. Dr. Jaradeh reported consulting fees from Alnylam, Akcea, and has received grant funding from Alnylam, outside of the submittedwork. Dr. Miglis has received consulting fees from 2nd MD, Infinite MD, and Jazz Pharmaceuticals, royalties from a health care publication, and grant funding from Ono Pharmaceuticals, the Agency for Healthcare Research and Quality (AHRQ), the National Institutes of Health, and Dysautonomia International, outside the submitted work. ### Funding Statement The study was funded by Dysautonomia International (East Moriches, New York) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: IRB of Stanford University gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors.
Public
Tom Kindlon

Immune disturbances in individuals with post-COVID syndrome are not characterized by enhanced SARS-CoV-2-specific immunity

dx.doi.org/10.1093/infdis/jiaf

"Persistent immune disturbances in individuals with PCS are characterized by reduced #SARSCoV2 -specific T cell responses, increased B cell activation, and altered inflammatory and vascular biomarkers."

@longcovid
#LongCovid #PwLC #PostCovidSyndrome #LC #PASC #postcovid
#CovidBrain @covid19 #COVIDー19 #COVID19 #COVID #COVID_19

Public
ahimsa

🗣️ Reminder - May 12 is International ME Awareness Day!

Want to join #MEAction's Millions Missing 2025 protest in Washington, DC but can't go in person?

You can attend virtually by submitting a photo of yourself:

airtable.com/appvOnNOiTgI2nkvZ

🚨Deadline is May 5th! (end of day)🚨

Find more advocacy actions on the main Millions Missing 2025 website:

meactions.org/millionsmissing2

@mecfs @longcovid

Millions Missing Photo Submission Inclusivity is one of our main priorities here at #MEAction. To make sure everyone is included in this year's #MillionsMissing 2025: SOS Protest in Washington, DC, please submit a photo of yourself. Submitted photos will either be displayed or carried by individual protesters. How the photos will be displayed at the protest site will depend on the amount of pictures we receive. Deadline to submit your photo is Monday, May 5th EOD.
#MEcfs#PwME#LongCovid
SearchLive feeds
About